20-F: SciSparc Ltd. Files 20-F Annual Report, Details Cannabinoid Therapy Development and AutoMax Merger

SciSparc Ltd. files its 20-F annual report, highlighting its focus on cannabinoid therapies, clinical development programs, and the proposed merger with AutoMax Motors Ltd.

Summary

• SciSparc Ltd., a specialty clinical-stage pharmaceutical company, filed its 20-F annual report for the fiscal year ended December 31, 2024.
• The company focuses on developing cannabinoid therapies, including SCI-110 for Tourette syndrome and Alzheimer's disease, and SCI-210 for Autism Spectrum Disorder.
• SciSparc also has a majority-owned subsidiary, SciSparc Nutraceuticals, involved in the sale of hemp seed oil-based products on Amazon Marketplace, generating $1.306 million in revenue for 2024.
• The report discusses the proposed merger with AutoMax Motors Ltd., targeting completion by September 30, 2025, subject to shareholder and regulatory approvals.
• SciSparc's cash reserves were approximately $2.1 million as of December 31, 2024, and the company anticipates needing additional funding.
• The company incurred a net loss of approximately $7.5 million for the year ended December 31, 2024, and has an accumulated deficit of approximately $75 million.
• The report includes a going concern explanatory paragraph from the independent registered public accounting firm.
• SciSparc is pursuing a restructuring plan, potentially involving the transfer of pharmaceutical activities to a subsidiary and listing it on a stock exchange.
• The company faces risks related to clinical development, regulatory approvals, reliance on third parties, intellectual property, and operations in Israel.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are ongoing clinical trials and a potential merger, the company's financial situation is precarious, with significant losses and a going concern warning. The sentiment is therefore cautiously negative.

Positives

• SciSparc is actively engaged in clinical development programs for multiple cannabinoid-based therapies.
• The company has a revenue-generating subsidiary, SciSparc Nutraceuticals, with sales on Amazon Marketplace.
• SciSparc is pursuing a merger with AutoMax Motors Ltd., which could provide diversification and new opportunities.
• The company has an exclusive license agreement with Yissum Research Development Company.
• SciSparc has a Scientific Advisory Board of eleven award winning and active physicians and scientists.

Negatives

• SciSparc has incurred significant losses and has a substantial accumulated deficit.
• The company's cash position is not sufficient to fund operations for the next 12 months, raising concerns about its ability to continue as a going concern.
• The proposed merger with AutoMax is subject to various conditions and may not be completed.
• The company faces risks related to clinical development, regulatory approvals, and reliance on third parties.
• The company's share price has been volatile and may be subject to further decline.

Risks

• The company's financial condition and capital requirements pose a significant risk to its ability to continue operations.
• Clinical drug development is a lengthy and expensive process with an uncertain outcome.
• The company relies on third parties for preclinical and clinical studies, manufacturing, and other tasks.
• The company's intellectual property rights may be challenged or infringed upon.
• The company's operations in Israel are subject to political, economic, and military instability.
• The proposed merger with AutoMax may not be completed or may not achieve the expected results.
• The company may be unable to successfully integrate or execute its new subsidiarys eCommerce operations business.
• The company will need additional capital in the future, and raising additional capital by issuing securities may cause dilution to existing shareholders.

Future Outlook

SciSparc anticipates needing additional funding to continue its operations and is pursuing a restructuring plan, potentially involving the transfer of pharmaceutical activities to a subsidiary and listing it on a stock exchange. The company is also planning a merger with AutoMax Motors Ltd., targeting completion by September 30, 2025.

Industry Context

The biotechnology and pharmaceutical industries are highly competitive, with many companies engaged in the research and development of similar products. SciSparc faces competition from established pharmaceutical companies, biotechnology companies, and research organizations.

Comparison to Industry Standards

• GW Pharmaceuticals (now part of Jazz Pharmaceuticals) received FDA approval for Epidiolex, a CBD-based drug for epilepsy, setting a precedent for cannabinoid-based pharmaceuticals.
• Companies like Zynerba Pharmaceuticals are developing transdermal CBD formulations for conditions like Fragile X and ASD, indicating a trend towards alternative delivery methods.
• RespireRx Pharmaceuticals is developing dronabinol for OSA treatment, showcasing the potential of cannabinoids in addressing sleep disorders.
• The market for orphan drugs, which SciSparc is targeting, typically sees high pricing, but the company's repurposed drug approach may face market resistance.

Legal Proceedings

• Capital Point Ltd. filed a lawsuit against SciSparc in connection with a warrant to purchase ordinary shares.
• SciSparc settled a lawsuit against its former directors related to breaches of fiduciary duties.

Related Party Transactions

• SciSparc has entered into a cooperation agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, the Companys Chief Technologies Officer, Mr. Weiss, the Companys President, and Mr. Adler, the Companys Chief Executive Officer and Chief Financial Officer serve as officers and directors.
• SciSparc has entered into the Polyrizon Collaboration Agreement with Polyrizon, a company in which Mr. Oz Adler, the Companys Chief Executive Officer and Chief Financial Officer, serves as a director.
• SciSparc has entered into the Wellution Sale Agreement with Jeffs Brands and Jeffs Holdings. Mr. Oz Adler, the Companys Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of Jeffs Brands, Mr. Amitay Weiss, our chairman of the board of directors and Mr. Moshe Revach, a member of our board of directors, are both directors in Jeffs Brands.
• SciSparc has entered into a Bridge Loan with AutoMax, a company in which Mr. Amitay Weiss, our chairman of the board of directors is the chairman of the board of directors of AutoMax.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by the company's restructuring plan.
• Customers of SciSparc Nutraceuticals may experience changes in product availability or pricing.
• Suppliers and creditors may be impacted by the company's financial condition and ability to meet its obligations.

Next Steps

• Complete the proposed merger with AutoMax Motors Ltd.
• Continue clinical development of SCI-110 and SCI-210.
• Seek regulatory approvals for product candidates.
• Secure additional funding to support operations.
• Implement the restructuring plan, potentially involving the transfer of pharmaceutical activities to a subsidiary and listing it on a stock exchange.

Key Dates

Keywords

SciSparc, cannabinoid therapies, clinical development, AutoMax, merger, pharmaceutical, Tourette syndrome, Alzheimer's disease, Autism Spectrum Disorder, financial results, risk factors, intellectual property, Israel, Wellution, SPRC